Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs

ConclusionsThere is an important evidence gap for the safety of drugs being repurposed for COVID-19. This uncertainty could cause unnecessary additional morbidity and mortality during the pandemic. We recommend caution in experimental drug use for non-severe disease and urge clinical trial sponsors to report missing results retrospectively.
Source: Trials - Category: Research Source Type: clinical trials